Zynex (NASDAQ:ZYXI – Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04), Briefing.com reports. The company had revenue of $49.88 million during the quarter, compared to the consensus estimate of $51.99 million. Zynex had a net margin of 3.12% and a return on equity of 13.14%. The company’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.09 earnings per share.
Zynex Stock Performance
ZYXI opened at $8.93 on Friday. The business’s 50-day simple moving average is $9.55 and its 200 day simple moving average is $11.06. Zynex has a 52-week low of $6.88 and a 52-week high of $13.77. The company has a debt-to-equity ratio of 1.76, a quick ratio of 2.87 and a current ratio of 3.58. The firm has a market capitalization of $283.71 million, a PE ratio of 38.83 and a beta of 0.53.
Analyst Ratings Changes
A number of analysts have recently commented on ZYXI shares. HC Wainwright cut their price target on Zynex from $21.00 to $16.00 and set a “buy” rating on the stock in a report on Friday. Royal Bank of Canada cut their target price on Zynex from $15.00 to $12.00 and set an “outperform” rating on the stock in a research note on Friday.
About Zynex
Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.
Read More
- Five stocks we like better than Zynex
- How to Use Stock Screeners to Find Stocks
- Why Call Options Volume for These 2 Stocks Spiked Together
- What is MarketRank™? How to Use it
- MarketBeat Week in Review – 7/22 – 7/26
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.
